<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Aqr International Multi-style Fund Class R6 — News on 6ix</title>
    <link>https://6ix.com/company/aqr-international-multi-style-fund-class-r6</link>
    <description>Latest news and press releases for Aqr International Multi-style Fund Class R6 on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 21 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/aqr-international-multi-style-fund-class-r6" rel="self" type="application/rss+xml" />
    <item>
      <title>Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States</title>
      <link>https://6ix.com/company/aqr-international-multi-style-fund-class-r6/news/wave-life-sciences-announces-hearing-on-proposed-redomiciliation-to-the-united-states-16</link>
      <guid isPermaLink="true">https://6ix.com/company/aqr-international-multi-style-fund-class-r6/news/wave-life-sciences-announces-hearing-on-proposed-redomiciliation-to-the-united-states-16</guid>
      <pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company</description>
    </item>
    <item>
      <title>F&amp;M Bank Announces Appointment of Shalini Singhal to Chief Information and Technology Officer</title>
      <link>https://6ix.com/company/aqr-international-multi-style-fund-class-r6/news/fandm-bank-announces-appointment-of-shalini-singhal-to-chief-information-and-technology-officer-57</link>
      <guid isPermaLink="true">https://6ix.com/company/aqr-international-multi-style-fund-class-r6/news/fandm-bank-announces-appointment-of-shalini-singhal-to-chief-information-and-technology-officer-57</guid>
      <pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
      <description>ARCHBOLD, Ohio, April 21, 2026 (GLOBE NEWSWIRE) -- F&amp;M Bank (“F&amp;M”), an Archbold, Ohio-based bank owned by Farmers &amp; Merchants Bancorp, Inc. (Nasdaq: FMAO),</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting</title>
      <link>https://6ix.com/company/aqr-international-multi-style-fund-class-r6/news/black-diamond-therapeutics-announces-oral-presentation-of-silevertinib-phase-2-data-in-frontline-egfrm-nsclc-patients-at-the-2026-asco-annual-meeting-4</link>
      <guid isPermaLink="true">https://6ix.com/company/aqr-international-multi-style-fund-class-r6/news/black-diamond-therapeutics-announces-oral-presentation-of-silevertinib-phase-2-data-in-frontline-egfrm-nsclc-patients-at-the-2026-asco-annual-meeting-4</guid>
      <pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
      <description>Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the randomized</description>
    </item>
    <item>
      <title>IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma</title>
      <link>https://6ix.com/company/aqr-international-multi-style-fund-class-r6/news/ideaya-biosciences-announces-late-breaking-abstract-oral-presentation-at-asco-2026-to-provide-complete-data-from-phase-23-registrational-trial-optimum-02-of-darovasertib-in-combination-with-crizotinib-in-1l-hlaa2-negative-metastatic-uveal-melanoma-3</link>
      <guid isPermaLink="true">https://6ix.com/company/aqr-international-multi-style-fund-class-r6/news/ideaya-biosciences-announces-late-breaking-abstract-oral-presentation-at-asco-2026-to-provide-complete-data-from-phase-23-registrational-trial-optimum-02-of-darovasertib-in-combination-with-crizotinib-in-1l-hlaa2-negative-metastatic-uveal-melanoma-3</guid>
      <pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., April 21, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today</description>
    </item>
    <item>
      <title>Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting</title>
      <link>https://6ix.com/company/aqr-international-multi-style-fund-class-r6/news/disc-medicine-announces-oral-presentation-of-data-from-rally-mf-phase-2-trial-of-disc-0974-in-patients-with-myelofibrosis-and-anemia-at-the-american-society-of-clinical-oncology-asco-annual-meeting-10</link>
      <guid isPermaLink="true">https://6ix.com/company/aqr-international-multi-style-fund-class-r6/news/disc-medicine-announces-oral-presentation-of-data-from-rally-mf-phase-2-trial-of-disc-0974-in-patients-with-myelofibrosis-and-anemia-at-the-american-society-of-clinical-oncology-asco-annual-meeting-10</guid>
      <pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
      <description>WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,</description>
    </item>
  </channel>
</rss>